Evidence map›Paper›PMID 33141837›Full record

ArticlePLoS neglected tropical diseases2020

Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus.

Haley L DeMers, Shihua He, Sujata G Pandit, Emily E Hannah, Zirui Zhang, Feihu Yan, Heather R Green, Denise F Reyes, Derrick Hau, Megan E McLarty and 5 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.Recent advances in anti-infective drug discovery · 2024
    Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Haley L DeMersDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.
Shihua HeSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Sujata G PanditDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.ORCID 0000-0003-2853-7822
Emily E HannahDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.ORCID 0000-0001-6957-5759
Zirui ZhangSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Feihu YanDepartment of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.
Heather R GreenDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.ORCID 0000-0002-8016-2100
Denise F ReyesDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.
Derrick HauDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.ORCID 0000-0002-4301-6403
Megan E McLartyDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.ORCID 0000-0002-2008-8914
Louis AltamuraDiagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America.
Cheryl Taylor-HowellDiagnostic Systems Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America.
Marcellene A Gates-HollingsworthDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.
Xiangguo QiuSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
David P AuCoinDepartment of Microbiology and Immunology, University of Nevada, Reno School of Medicine Reno, Nevada, United States of America.ORCID 0000-0002-2197-8177
University of Nevada, Reno · USPublic Health Agency of Canada · CAUnited States Army Medical Research Institute of Infectious Diseases · USUniversity of Manitoba · CA

Funding

Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)R41AI149940 · NIAID · INBIOS INTERNATIONAL, INC. · PI AUCOIN, DAVID P, RAYCHAUDHURI, SYAMAL X · 2020 to 2021
$598k
NIAID NIH HHS R41 AI149940
6 · The paper itself

Abstract

The 2013-2016 Ebola virus (EBOV) outbreak in West Africa and the ongoing cases in the Democratic Republic of the Congo have spurred development of a number of medical countermeasures, including rapid Ebola diagnostic tests. The likelihood of transmission increases as the disease progresses due to increasing viral load and potential for contact with others. Early diagnosis of EBOV is essential for halting spread of the disease. Polymerase chain reaction assays are the gold standard for diagnosing Ebola virus disease (EVD), however, they rely on infrastructure and trained personnel that are not available in most resource-limited settings. Rapid diagnostic tests that are capable of detecting virus with reliable sensitivity need to be made available for use in austere environments where laboratory testing is not feasible. The goal of this study was to produce candidate lateral flow immunoassay (LFI) prototypes specific to the EBOV glycoprotein and viral matrix protein, both targets known to be present during EVD. The LFI platform utilizes antibody-based technology to capture and detect targets and is well suited to the needs of EVD diagnosis as it can be performed at the point-of-care, requires no cold chain, provides results in less than twenty minutes and is low cost. Monoclonal antibodies were isolated, characterized and evaluated in the LFI platform. Top performing LFI prototypes were selected, further optimized and confirmed for sensitivity with cultured live EBOV and clinical samples from infected non-human primates. Comparison with a commercially available EBOV rapid diagnostic test that received emergency use approval demonstrates that the glycoprotein-specific LFI developed as a part of this study has improved sensitivity. The outcome of this work presents a diagnostic prototype with the potential to enable earlier diagnosis of EVD in clinical settings and provide healthcare workers with a vital tool for reducing the spread of disease during an outbreak.

Indexed as

AnimalsAntibodies, MonoclonalAntigens, ViralDemocratic Republic of the CongoDiagnostic Tests, RoutineDisease OutbreaksEbolavirusEnzyme-Linked Immunosorbent AssayFemaleHemorrhagic Fever, EbolaHumansImmunoassayImmunologic TestsMicePoint-of-Care SystemsPoint-of-Care TestingAntibodies, MonoclonalAntigens, Viralenvelope glycoprotein, Ebola virusViral Envelope ProteinsViral Matrix Proteins

Identifiers

PMID33141837
PMCPMC7608863
OpenAlexW3096674160

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.